Company intelligence / Profile preview

Advance Tests

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Advance Tests provides a CE-marked blood-based diagnostic test, LucentAD Complete, for Alzheimer's risk screening. The test reports over 90% accuracy in detecting amyloid pathology using p-Tau 217, aligning with international standards and meeting Alzheimer's Association criteria. Results are delivered within 15 working days directly to patients and referring physicians.

Therapeutic areas: Neurology
Modalities: Diagnostic test (Biologic assay)
Industry: Protein Biomarker Diagnostics

Partnerships

Centre for Applied and Inclusive Health Research at the University of Wolverhampton

Beyond the preview

Go deeper on Advance Tests.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advance Tests.

Explore the full profile